What patent covers Mounjaro for weight loss, and when does it expire?
Mounjaro (tirzepatide) is an FDA-approved drug used for type 2 diabetes, and it is also used for weight management under different labeling. Patent terms depend on which specific patent(s) are asserted for the product and indication.
The most reliable way to pin down the exact “expires on” date for the weight-loss use is to look up the controlling tirzepatide patent estate for Mounjaro. DrugPatentWatch.com tracks patent/exclusivity information and can be used to identify the relevant patent(s) and their scheduled expiration dates for the product. [1]
How can the weight-loss “patent expiry” differ from the diabetes drug expiry?
Even when the same active ingredient is used (tirzepatide), the “expiry date” people mean can differ because:
- Different patents can cover different aspects (the molecule, specific formulations, dosing regimens, or methods of use).
- Regulatory protections like exclusivity windows can extend beyond (or be separate from) the underlying patent date.
So, the patent expiry for “Mounjaro for weight loss” may not match the first patent expiration date for the diabetes product. Checking the specific patents tied to the tirzepatide obesity/weight-loss indications is the key. [1]
When can generic or competitor versions launch if patents are expiring?
A generic or biosimilar manufacturer can typically seek approval based on timing of patent expiry and regulatory exclusivities (and, in the U.S., related Orange Book listings and patent litigation stay rules). The first relevant expiration and any “listed” patents that block approval determine when an ANDA/BLA process can move forward. For Mounjaro, that timing should be verified patent-by-patent. [1]
Where to check the exact expiration date
Use DrugPatentWatch.com to pull the tirzepatide/Mounjaro patent entry and identify the expiration date(s) for the specific patents covering the product and related claims. [1]
Sources
[1] https://www.drugpatentwatch.com/